AXL and c-Met Dual-Targeting in Non-Small Cell Lung Cancer: A Review of Small-Molecule Inhibitors and Their...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• AXL and c-Met are key oncogenic drivers in non-small cell lung cancer (NSCLC).
• These pathways exhibit significant cross-talk, influencing tumor progression and drug resistance.
• Molecular targeted therapy presents an advantage in NSCLC management due to its precision and low toxicity.

Purpose of the Study:

• To systematically review the structure, function, regulation, and signaling of AXL and c-Met.
• To highlight advancements in small molecule co-targeted inhibitors of AXL and c-Met.
• To summarize clinical trial outcomes for this therapeutic strategy in NSCLC.

Main Methods:

• Systematic literature review of AXL and c-Met.
• Analysis of small molecule co-targeted inhibitors.
• Summary of preclinical and clinical trial data.

Main Results:

• AXL and c-Met impact NSCLC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
• Co-targeting these factors demonstrates substantial anti-tumor efficacy.
• Small molecule inhibitors targeting both AXL and c-Met are under active investigation.

Conclusions:

• Co-targeting AXL and c-Met is a promising therapeutic strategy for NSCLC.
• This approach addresses key mechanisms of tumor growth and resistance.
• Further clinical evaluation is warranted to optimize treatment outcomes.